Gilead Sciences News

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

fool.com · Jul 12, 2026

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

zacks.com · Jul 10, 2026

2 Recession-Resistant Dividend Stocks to Buy and Hold

fool.com · Jul 10, 2026

A Look at Gilead Sciences Inc (GILD) After 5.2% Gain -- GF Value $96.06 vs Price $136.36

gurufocus.com · Jul 7, 2026

Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”

247wallst.com · Jul 7, 2026

Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?

zacks.com · Jul 6, 2026

Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says

benzinga.com · Jul 6, 2026

Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More

247wallst.com · Jul 6, 2026

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

zacks.com · Jul 2, 2026

Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?

zacks.com · Jun 29, 2026

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

zacks.com · Jun 25, 2026

Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use

zacks.com · Jun 25, 2026

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

businesswire.com · Jun 24, 2026

Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC

zacks.com · Jun 24, 2026

Gilead Sciences: The Market Is Underestimating Its Growth Runway

seekingalpha.com · Jun 23, 2026

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

businesswire.com · Jun 23, 2026

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

zacks.com · Jun 18, 2026

The Healthcare M&A Wave

forbes.com · Jun 17, 2026

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

zacks.com · Jun 16, 2026

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

zacks.com · Jun 15, 2026

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

businesswire.com · Jun 15, 2026

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

businesswire.com · Jun 12, 2026

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

zacks.com · Jun 11, 2026

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

businesswire.com · Jun 11, 2026

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

etftrends.com · Jun 11, 2026

Can Gilead Sciences HIV Franchise Drive Long-Term Growth?

zacks.com · Jun 10, 2026

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com · Jun 9, 2026

Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study

zacks.com · Jun 9, 2026

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

benzinga.com · Jun 9, 2026

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

businesswire.com · Jun 8, 2026

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

businesswire.com · Jun 8, 2026

Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead

marketbeat.com · Jun 8, 2026

Baron Discovery Fund Q1 2026: Who Moved The Needle

seekingalpha.com · Jun 8, 2026

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

seekingalpha.com · Jun 5, 2026

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

marketbeat.com · Jun 5, 2026

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

businesswire.com · Jun 5, 2026

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

businesswire.com · Jun 4, 2026

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

globenewswire.com · Jun 4, 2026

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

zacks.com · Jun 4, 2026

Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?

fool.com · Jun 4, 2026

GILD Reports Positive Results From Late-Stage Liver Disease Study

zacks.com · Jun 3, 2026

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

zacks.com · Jun 3, 2026

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome

benzinga.com · Jun 2, 2026

Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

businesswire.com · Jun 2, 2026

Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

seekingalpha.com · May 29, 2026

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1--1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)

gurufocus.com · May 27, 2026

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)

businesswire.com · May 27, 2026

GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy

zacks.com · May 25, 2026

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

marketbeat.com · May 24, 2026

US FDA approves Gilead's drug for deadly liver infection

reuters.com · May 22, 2026

FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

businesswire.com · May 22, 2026

FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

gurufocus.com · May 22, 2026

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

businesswire.com · May 22, 2026

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

businesswire.com · May 21, 2026

Why Gilead Sciences Is Now A Hold (Rating Upgrade)

seekingalpha.com · May 21, 2026

Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now

247wallst.com · May 21, 2026

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

businesswire.com · May 21, 2026

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

gurufocus.com · May 21, 2026

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

businesswire.com · May 21, 2026

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

zacks.com · May 20, 2026